New Pan-Asian-adapted recommendations on gastric cancer and early breast cancer presented by ESMO
The two Pan-Asian Guideline Adaptations of parental ESMO Clinical Practice Guidelines reflect the younger age of disease occurrence and lack of some treatment data in Asia
Real-world data give insights into toxicities associated with immunotherapy
Novel approaches including the use of a JAK-STAT inhibitor, a nomogram and assessment of eosinophil proportions are presented for improving the management of immune-related adverse events
Targeted therapy shows early promise in EBV-positive nasopharyngeal carcinoma
In an early-phase study, the selective inhibitor nanatinostat was well tolerated with evidence of antitumour activity in combination with antiviral therapy
Adjuvant immunotherapy reduces relapse risk in resected or ablated hepatocellular cancer
Data from the IMbrave050 study show benefits of atezolizumab plus bevacizumab in terms of disease recurrence, but long-term data are needed
Pembrolizumab plus chemotherapy prolongs survival in pleural mesothelioma
In the IND227 trial, more pronounced benefits of the immunotherapy were observed in patients with non-epithelioid histology and regardless of PD-L1 status
Dostarlimab shows preliminary but durable activity across multiple cancers
Promising data are reported for tumours with dMMR, MSI-H and rare POLE alterations, reinforcing the role of molecular testing for tissue-agnostic treatment
Adding atezolizumab to bevacizumab and chemotherapy improves outcomes in metastatic cervical cancer
Results from the BEATcc study strongly support the use of first-line combination therapy for R/M CC in all patients
Antibody–drug conjugates improve outcomes for patients with inoperable or metastatic breast cancer
Promising results reported for datopotamab deruxtecan and trastuzumab deruxtecan in HER2-non-amplified breast cancer
Amivantamab combination therapies emerge as new options for EGFR-mutated advanced NSCLC
Clinically meaningful improvements over standard care were observed in both first and second line, as reported in the MARIPOSA and MARIPOSA-2 phase III trials
Datopotamab deruxtecan met the PFS endpoint in previously treated NSCLC
The TROP2-directed ADC improved PFS with reduced toxicity compared with chemotherapy in the TROPION-Lung01 trial, but results are not practice-changing